53 related articles for article (PubMed ID: 27505668)
1. IDH1, Histone Methylation, and So Forth.
Penard-Lacronique V; Bernard OA
Cancer Cell; 2016 Aug; 30(2):192-194. PubMed ID: 27505668
[TBL] [Abstract][Full Text] [Related]
2. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
3. Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.
Jin Y; Elalaf H; Watanabe M; Tamaki S; Hineno S; Matsunaga K; Woltjen K; Kobayashi Y; Nagata S; Ikeya M; Kato T; Okamoto T; Matsuda S; Toguchida J
PLoS One; 2015; 10(7):e0131998. PubMed ID: 26161668
[TBL] [Abstract][Full Text] [Related]
4. Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers.
Bledea R; Vasudevaraja V; Patel S; Stafford J; Serrano J; Esposito G; Tredwin LM; Goodman N; Kloetgen A; Golfinos JG; Zagzag D; Weigelt B; Iafrate AJ; Sulman EP; Chi AS; Dogan S; Reis-Filho JS; Chiang S; Placantonakis D; Tsirigos A; Snuderl M
Sci Rep; 2019 Nov; 9(1):16830. PubMed ID: 31727977
[TBL] [Abstract][Full Text] [Related]
5. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
7. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Whitehall VL; Dumenil TD; McKeone DM; Bond CE; Bettington ML; Buttenshaw RL; Bowdler L; Montgomery GW; Wockner LF; Leggett BA
Epigenetics; 2014 Nov; 9(11):1454-60. PubMed ID: 25496513
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
10. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Upadhyay VA; Brunner AM; Fathi AT
Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
13. IDH1 mutations in gliomas: when an enzyme loses its grip.
Frezza C; Tennant DA; Gottlieb E
Cancer Cell; 2010 Jan; 17(1):7-9. PubMed ID: 20129244
[TBL] [Abstract][Full Text] [Related]
14. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Calvert AE; Chalastanis A; Wu Y; Hurley LA; Kouri FM; Bi Y; Kachman M; May JL; Bartom E; Hua Y; Mishra RK; Schiltz GE; Dubrovskyi O; Mazar AP; Peter ME; Zheng H; James CD; Burant CF; Chandel NS; Davuluri RV; Horbinski C; Stegh AH
Cell Rep; 2017 May; 19(9):1858-1873. PubMed ID: 28564604
[TBL] [Abstract][Full Text] [Related]
15. Bringing IDH into the Fold.
Zadeh G; Aldape K
Cancer Cell; 2016 Feb; 29(2):139-40. PubMed ID: 26859452
[TBL] [Abstract][Full Text] [Related]
16. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
17. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.
Dimitrov L; Hong CS; Yang C; Zhuang Z; Heiss JD
Int J Med Sci; 2015; 12(3):201-13. PubMed ID: 25678837
[TBL] [Abstract][Full Text] [Related]
18. Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Kim HJ; Fei X; Cho SC; Choi BY; Ahn HC; Lee K; Seo SY; Keum YS
Bioorg Med Chem Lett; 2015 Dec; 25(23):5625-31. PubMed ID: 26508549
[TBL] [Abstract][Full Text] [Related]
19. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
20. Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart.
Karlstaedt A; Zhang X; Vitrac H; Harmancey R; Vasquez H; Wang JH; Goodell MA; Taegtmeyer H
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10436-41. PubMed ID: 27582470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
